Multiparametric MRI of the bladder: Ready for clinical routine?

American Journal of Roentgenology

Volumn 202, Issue 6, 2014, Pages 1187-1195

  De Haas, Robbert J ^a   Steyvers, Maarten J ^a   Fütterer, Jurgen J ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Bladder; Bladder cancer; Multiparametric MRI

Indexed keywords

BLADDER CANCER; CANCER PROGNOSIS; CANCER STAGING; CONTRAST ENHANCEMENT; DIAGNOSTIC IMAGING; DIFFUSION WEIGHTED IMAGING; HUMAN; IMAGE DISPLAY; IMAGE QUALITY; INTERMETHOD COMPARISON; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; REVIEW; SENSITIVITY AND SPECIFICITY; AGED; BLADDER; BLADDER TUMOR; DIAGNOSTIC TEST; FEMALE; IMAGE ENHANCEMENT; MALE; METHODOLOGY; MIDDLE AGED; MULTIMODAL IMAGING; PATHOLOGY;

AGED; DIAGNOSTIC TESTS, ROUTINE; FEMALE; HUMANS; IMAGE ENHANCEMENT; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIMODAL IMAGING; NEOPLASM STAGING; URINARY BLADDER; URINARY BLADDER NEOPLASMS;

EID: 84904107396     PISSN: 0361803X     EISSN: 15463141     Source Type: Journal    
DOI: 10.2214/AJR.13.12294     Document Type: Review

References (46)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008; 58:71-96 (Pubitemid 351521864)
2. Verma S, Rajesh A, Prasad SR, et al. Urinary bladder cancer: role of MR imaging. RadioGraphics 2012; 32:371-387
3. Sobin LH, Wittekind Ch. TNM classification of malignant tumours, 6th ed. Hoboken, NJ: Wiley, 2002
4. Shariat SF, Palapattu GS, Karakiewicz PI, et al. Discrepancy between clinical and pathologic stage: impact on prognosis after radical cystectomy. Eur Urol 2007; 51:137-149
5. Svatek RS, Shariat SF, Novara G, et al. Discrepancy between clinical and pathological stage: external validation of the impact on prognosis in an international radical cystectomy cohort. BJU Int 2011; 107:898-904
6. Green DA, Durand M, Gumpeni N, et al. Role of magnetic resonance imaging in bladder cancer: current status and emerging techniques. BJU Int 2012; 110:1463-1470
7. Tekes A, Kamel I, Imam K, et al. Dynamic MRI of bladder cancer: evaluation of staging accuracy. AJR 2005; 184:121-127 (Pubitemid 40040915)
8. Bryan PJ, Butler HE. LiPuma JP, Resnick MI, Kursh ED. CT and MR imaging in staging bladder neoplasms. J Comput Assist Tomogr 1987; 11:96-101 (Pubitemid 17231471)
9. Dixon AK, Deane AM, Doyle PT. Computed tomography and magnetic resonance imaging before salvage cystectomy. Br J Urol 1990; 66:42-46 (Pubitemid 20227996)
10. Husband JE, Olliff JF, Williams MP, Heron CW, Cherryman GR. Bladder cancer: staging with CT and MR imaging. Radiology 1989; 173:435-440 (Pubitemid 19264601)
11. Kim B, Semelka RC, Ascher SM, Chalpin DB, Carroll PR, Hricak H. Bladder tumor staging: comparison of contrast-enhanced CT, T1- and T2-weighted MR imaging, dynamic gadolinium-enhanced imaging, and late gadolinium-enhanced imaging. Radiology 1994; 193:239-245
12. Rajesh A, Sokhi HK, Fung R, Mulcahy KA, Bankart MJ. Bladder cancer: evaluation of staging accuracy using dynamic MRI. Clin Radiol 2011; 66:1140-1145
13. Tritschler S, Mosler C, Straub J, et al. Staging of muscle-invasive bladder cancer: can computerized tomography help us to decide on local treatment? World J Urol 2012; 30:827-831
14. El-Assmy A, Abou-El-Ghar ME, Mosbah A, et al. Bladder tumour staging: comparison of diffusion- and T2-weighted MR imaging. Eur Radiol 2009; 19:1575-1581
15. Takeuchi M, Sasaki S, Ito M, et al. Urinary bladder cancer: diffusion-weighted MR imaging - accuracy for diagnosing T stage and estimating histologic grade. Radiology 2009; 251:112-121
16. Barentsz JO, Ruijs SH, Strijk SP. The role of MR imaging in carcinoma of the urinary bladder. AJR 1993; 160:937-947 (Pubitemid 23141230)
17. Hood MN, Ho VB, Smirniotopoulos JG, Szumowski J. Chemical shift: the artifact and clinical tool revisited. RadioGraphics 1999; 19:357-371
18. Lawler LP. MR imaging of the bladder. Radiol Clin North Am 2003; 41:161-177 (Pubitemid 36259130)
19. Tekes A, Kamel IR, Imam K, Chan TY, Schoenberg MP, Bluemke DA. MR imaging features of transitional cell carcinoma of the urinary bladder. AJR 2003; 180:771-777 (Pubitemid 36237227)
20. Daniel BL, Shimakawa A, Blum MR, Herfkens RJ. Single-shot fluid attenuated inversion recovery (FLAIR) magnetic resonance imaging of the bladder. J Magn Reson Imaging 2000; 11:673-677 (Pubitemid 30350311)
21. Totaro A, Pinto F, Bescia A, et al. Imaging in bladder cancer: present role and future perspectives. Urol Int 2010; 85:373-380
22. Hoeks CM, Barentsz JO, Hambrock T, et al. Prostate cancer: multiparametric MR imaging for detection, localization, and staging. Radiology 2011; 261:46-66
23. Hafeez S, Huddart R. Advances in bladder cancer imaging. BMC Med 2013; 11:104
24. Hamstra DA, Rehemtulla A, Ross BD. Diffusion magnetic resonance imaging: a biomarker for treatment response in oncology. J Clin Oncol 2007; 25:4104-4109 (Pubitemid 47495868)
25. Matsuki M, Inada Y, Tatsugami F, Tanikake M, Narabayashi I, Katsuoka Y. Diffusion-weighted MR imaging for urinary bladder carcinoma: initial results. Eur Radiol 2007; 17:201-204 (Pubitemid 46063045)
26. Abou-El-Ghar ME, El-Assmy A, Refaie HF, El-Diasty T. Bladder cancer: diagnosis with diffusion-weighted MR imaging in patients with gross hematuria. Radiology 2009; 251:415-421
27. Kobayashi S, Koga F, Yoshida S, et al. Diagnostic performance of diffusion-weighted magnetic resonance imaging in bladder cancer: potential utility of apparent diffusion coefficient values as a biomarker to predict clinical aggressiveness. Eur Radiol 2011; 21:2178-2186
28. Halefoglu AM, Sen EY, Tanriverdi O, Yilmaz F. Utility of diffusion-weighted MRI in the diagnosis of bladder cancer. Clin Imaging 2013; 37:1077-1083
29. Wu LM, Chen XX, Xu JR, et al. Clinical value of T2-weighted imaging combined with diffusion-weighted imaging in preoperative T staging of urinary bladder cancer: a large-scale, multiobserver prospective study on 3.0-T MRI. Acad Radiol 2013; 20:939-946
30. Watanabe H, Kanematsu M, Kondo H, et al. Preoperative T staging of urinary bladder cancer: does diffusion-weighted MRI have supplementary value? AJR 2009; 192:1361-1366
31. Kobayashi S, Koga F, Kajino K, et al. Apparent diffusion coefficient value reflects invasive and proliferative potential of bladder cancer. J Magn Reson Imaging 2014; 39:172-178
32. Yoshida S, Koga F, Kobayashi S, et al. Role of diffusion-weighted magnetic resonance imaging in predicting sensitivity to chemoradiotherapy in muscle-invasive bladder cancer. Int J Radiat Oncol Biol Phys 2012; 83:e21-e27
33. El-Assmy A, Abou-El-Ghar ME, Refaie HF, Mosbah A, El-Diasty T. Diffusion-weighted magnetic resonance imaging in follow-up of superficial urinary bladder carcinoma after transurethral resection: initial experience. BJU Int 2012; 110:E622-E627
34. Wang HJ, Pui MH, Guo Y, Yang D, Pan BT, Zhou XH. Diffusion-weighted MRI in bladder carcinoma: the differentiation between tumor recurrence and benign changes after resection. Abdom Imaging 2014; 39:135-141
35. Funatsu H, Imamura A, Takano H, Ueda T, Uno T. Can pretreatment ADC values predict recurrence of bladder cancer after transurethral resection? Eur J Radiol 2012; 81:3115-3119
36. Sourbron S. Technical aspects of MR perfusion. Eur J Radiol 2010; 76:304-313
37. Tuncbilek N, Kaplan M, Altaner S, et al. Value of dynamic contrast-enhanced MRI and correlation with tumor angiogenesis in bladder cancer. AJR 2009; 192:949-955
38. Donaldson SB, West CM, Davidson SE, et al. A comparison of tracer kinetic models for T1-weighted dynamic contrast-enhanced MRI: application in carcinoma of the cervix. Magn Reson Med 2010; 63:691-700
39. Donaldson SB, Bonington SC, Kershaw LE, et al. Dynamic contrast-enhanced MRI in patients with muscle-invasive transitional cell carcinoma of the bladder can distinguish between residual tumour and post-chemotherapy effect. Eur J Radiol 2013; 82:2161-2168
40. Barentsz JO, Jager GJ, van Vierzen PB, et al. Staging urinary bladder cancer after transurethral biopsy: value of fast dynamic contrast-enhanced MR imaging. Radiology 1996; 201:185-193 (Pubitemid 26314386)
41. Daneshmand S, Ahmadi H, Huynh LN, Dobos N. Preoperative staging of invasive bladder cancer with dynamic gadolinium-enhanced magnetic resonance imaging: results from a prospective study. Urology 2012; 80:1313-1318
42. Schrier BP, Peters M, Barentsz JO, Witjes JA. Evaluation of chemotherapy with magnetic resonance imaging in patients with regionally metastatic or unresectable bladder cancer. Eur Urol 2006; 49:698-703 (Pubitemid 43374733)
43. Deserno WM, Harisinghani MG, Taupitz M, et al. Urinary bladder cancer: preoperative nodal staging with ferumoxtran-10-enhanced MR imaging. Radiology 2004; 233:449-456 (Pubitemid 39423804)
44. Birkhäuser FD, Studer UE, Froehlich JM, et al. Combined ultrasmall superparamagnetic particles of iron oxide-enhanced an diffusion-weighted magnetic resonance imaging facilitates detection of metastases in normal-sized pelvic lymph nodes of patients with bladder and prostate cancer. Eur Urol 2013; 64:953-960
45. Triantafyllou M, Studer UE, Birkhäuser FD, et al. Ultrasmall superparamagnetic particles of iron oxide allow for the detection of metastases in normal sized pelvic lymph nodes of patients with bladder and/or prostate cancer. Eur J Cancer 2013; 49:616-624
46. Bostrom PJ, van Rhijn BW, Fleshner N, et al. Staging and staging errors in bladder cancer. Eur Urol Suppl 2010; 9:2-9